John H. Newman, MD; John A. Phillips, MD; James E. Loyd, MD
Grant Support: By an institutional research grant (M01-RR-00095) from General Clinical Research Center. Dr. Loyd is also supported by grant PO1 072058 from the National Institutes of Health, National Heart, Lung, and Blood Institute.
Potential Financial Conflicts of Interest:Grants received: J.A. Phillips III (National Institutes of Health). Grants pending: J.A. Phillips III (National Institutes of Health).
Request for Single Reprints: John H. Newman, MD, Division of Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, T 1219 Vanderbilt Medical Center North, Nashville, TN 37232-2650; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Newman: Division of Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, T 1219 Vanderbilt Medical Center North, Nashville, TN 37232-2650.
Dr. Phillips: Division of Medical Genetics, Vanderbilt University School of Medicine, DD 2205 Vanderbilt Medical Center North, Nashville, TN 37232-2650.
Dr. Loyd: Division of Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, T 1218 Vanderbilt Medical Center North, Nashville, TN 37232-2650.
Newman J., Phillips J., Loyd J.; Narrative Review: The Enigma of Pulmonary Arterial Hypertension: New Insights from Genetic Studies. Ann Intern Med. 2008;148:278-283. doi: 10.7326/0003-4819-148-4-200802190-00006
Download citation file:
Published: Ann Intern Med. 2008;148(4):278-283.
Pulmonary arterial hypertension (PAH) occurs as an idiopathic disease (formerly called primary pulmonary hypertension) and as a consequence of other illnesses. These illnesses include connective tissue diseases, portal hypertension, diet and stimulant drug use, HIV infection, and congenital heart disease. Inherited susceptibility to PAH occurs in families and is almost always due to mutations in genes of the TGF-Î² family of receptors. The most common mutation leading to PAH is in bone morphogenetic protein receptor type 2 (BMPR2), originally discovered to be involved in bone healing. Mutations in BMPR2 have also been found in patients with idiopathic PAH, although the true prevalence of this susceptibility has not been determined. About 20% of individuals with a BMPR2 mutation develop symptomatic pulmonary hypertension. Evidence is growing that imbalanced activation of other TGF-Î² receptors coupled with reduced activity of mutated BMPR2 increases the likelihood of development of PAH. Many signaling systems have been found to participate in PAH, including K channels, serotonin, angiopoietin, and cyclooxygenases. An interaction of these signaling systems with BMPR2 is a focus of research in PAH. Approaches to altering the imbalance of activation of BMPR2 and other TGF-Î² receptors may yield future therapies for PAH.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Pulmonary/Critical Care, Pulmonary Hypertension.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only